QCell P.C.

What QCell P.C. does

QCell P.C. is a Greek medical technology company founded in 2016 by Professor Costas Balas, headquartered in Chania, Crete, Greece. The company develops proprietary medical spectral imaging devices based on its Spectral Vision camera technology, which transforms conventional color camera-based medical scopes into AI-powered 4K-video spectral imagers operating across visible and near-infrared spectrum at video rates. QCell's product portfolio includes the Spectral View Dermoscope for skin lesion characterization, the DSI Colposcope for cervical neoplasia screening with dynamic acetowhitening analysis, In-Spect Endoscopes adaptable to rigid endoscopes across multiple surgical specialties, and the SAVE (Spectral Artificial Vision Examiner) handheld, low-cost spectral imager targeting cervical cancer and Female Genital Schistosomiasis screening in low- and middle-income countries.

QCell operates a hardware sales revenue model through direct enterprise field sales to healthcare providers and clinical institutions, with pricing handled on a request-for-quotation basis. The company holds ISO 13485 certification, CE-Marked products listed in EUDAMED, and proprietary patented Spectral Vision technology. Its go-to-market combines direct institutional sales with EU-funded project deployment, notably the DUALSAVE-FGS HORIZON Program 101057853 partnership spanning nine African and European institutions and supporting multicenter clinical trials in South Africa, Eswatini, and Mozambique. Customer segmentation is hybrid, spanning gynecology/colposcopy clinics, endoscopy/surgical centers, dermatology practices in developed markets, and primary healthcare providers in LMICs. The company has demonstrated strong clinical validation outcomes, including 97% sensitivity and 100% specificity for DSI Colposcopy in HPV-16 positive patients and 88% sensitivity versus 55% for conventional colposcopy.

Name

QCell P.C.

Legal name

QCell P.C.

Website

https://qcell.tech

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

QCell P.C. develops proprietary 4K snapshot spectral imaging medical devices—dermoscopes, colposcopes, endoscopes, and the SAVE handheld imager—for cervical cancer, FGS, dermatology, and endoscopy diagnostics, serving healthcare providers in Europe and LMICs.

Ownership category

akta.pro rank

Product category

Medical Spectral Imaging Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)

akta.pro primary industry

Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)

akta.pro secondary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• Medical spectral imaging
• Hyperspectral endoscopy devices
• Cervical cancer screening
• Spectral vision dermoscopy
• AI medical diagnostics

Headquarters

HQ city

Chaniá

HQ country

Greece

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: QCell generates revenue through the sale of medical spectral imaging devices including dermoscopes, colposcopes, and endoscopic camera systems. Products are certified (ISO 13485, CE-Marked) and listed in EUDAMED, enabling commercial distribution in European and international markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

QCell P.C. designs and manufactures medical spectral imaging devices based on its proprietary Spectral Vision camera technology. The portfolio includes the Spectral View Dermoscope for skin lesion characterization, the DSI Colposcope for cervical neoplasia screening, and the In-Spect Endoscopes adaptable to rigid endoscopes across multiple surgical specialties. The products transform conventional color-camera-based medical scopes into AI-powered 4K-video spectral imagers that reveal hidden diagnostic features through spectral signatures in both visible and near-infrared spectrum.

Product overview

QCell P.C. offers a portfolio of medical spectral imaging devices based on its proprietary Spectral Vision camera technology platform. The portfolio includes three commercial products: the Spectral View Dermoscope for skin lesion characterization, the DSI Colposcope for cervical neoplasia screening, and the In-Spect Endoscopes for spectral endoscopy. Additionally, the SAVE (Spectral Artificial Vision Examiner) handheld screening device targets cervical cancer and Female Genital Schistosomiasis screening in low- and middle-income countries. All products share the core Spectral Vision technology enabling AI-powered 4K-video spectral imaging that transforms color camera-based medical scopes from visualization tools into AI-powered diagnostic instruments.

Differentiator

Problem solved

Functional benefit

Brands

• inSpect Endoscopes: World's first 4K, video spectral imager adaptable to all rigid endoscopes for spectral endoscopy applications.
• DSI Colposcope
• Spectral View Dermoscope
• SAVE (Spectral Artificial Vision Examiner)

Products and services

• Spectral View Dermoscope World's first dermoscope offering spectral contrast enhancement, selective imaging of surface and subsurface invisible features, and skin lesion characterization through spectral characteristics measurement. Operates in reflectance and fluorescence imaging modes. Intended for dermatologists and skin cancer specialists.
• DSI Colposcope World's first snapshot spectral imaging colposcope that introduces spectral analysis of the dynamic optical effects of the acetowhitening test. Performs full spectrum time-lapse imaging of acetowhitening and measures/maps Lugol's Iodine uptake by cervical tissue at 4K resolution. Intended for gynecology and colposcopy clinics performing cervical cancer screening.
• In-Spect Endoscopes World's first 4K video spectral imager adaptable to all rigid endoscopes. Provides snapshot, video rate spectral imaging across 400-1000nm with 8 spectral bands and 6.4 million pixels per band. Includes NIR fluorescence imaging capacity for ICG and tumor-specific fluorophore imaging. Adapts to rigid endoscopes used in otolaryngology, orthopedics, neurosurgery, urology, gynecology/hysteroscopy, laparoscopy, and robotic endoscopy.
• SAVE (Spectral Artificial Vision Examiner) Novel low-cost hand-held imaging spectroscopy-based colposcope integrating advanced spectral imaging and machine learning technologies. Tablet/mobile phone connectable, video rate spectral imager that can identify Cervical Intraepithelial Neoplasia (CIN) and Female Genital Schistosomiasis (FGS) instantly and non-invasively. Battery operated and field deployable for single-person operation in primary healthcare settings.

Quantifiable outcome

• DSI Colposcopy demonstrated 97% sensitivity and 100% specificity to detecting CIN2+ lesions in patients who tested positive for HPV-16
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Oslo University Hospital (Norway)coreStrategic or Co-development PartnerPart of the DUALSAVE-FGS consortium of nine African and European institutions. Contributing clinical expertise and research capabilities to the cervical cancer and FGS screening technology validation.
• University of KwaZulu-Natal (South Africa)coreStrategic or Co-development PartnerDUALSAVE-FGS consortium partner providing clinical trial infrastructure in South Africa, one of the three countries where multicenter clinical validation is conducted.
• Durban University of Technology (South Africa)coreStrategic or Co-development PartnerDUALSAVE-FGS consortium partner contributing technical and research capabilities to the spectral imaging technology validation project.
• Centre Bilharzia and Tropical Health (BRIGHT)coreStrategic or Co-development PartnerDUALSAVE-FGS consortium partner specializing in bilharzia (schistosomiasis) and tropical health research, essential for FGS screening validation.
• University of Eswatini (Eswatini)coreStrategic or Co-development PartnerDUALSAVE-FGS consortium partner providing clinical trial site for multicenter validation in Eswatini, one of three African countries in the clinical study.
• University of Copenhagen (Denmark)minorStrategic or Co-development PartnerDUALSAVE-FGS consortium partner contributing academic research expertise to the cervical cancer and FGS screening technology initiative.
• Universidade Eduardo Mondlane (Mozambique)coreStrategic or Co-development PartnerDUALSAVE-FGS consortium partner providing clinical trial infrastructure in Mozambique, one of three countries in the international multicenter clinical validation.
• University of Agder (Norway)minorStrategic or Co-development PartnerDUALSAVE-FGS consortium partner contributing research capabilities to the spectral imaging and screening technology project.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Resonon: Hyperspectral imaging camera manufacturer serving research, remote sensing, and machine-vision markets — overlap with QCell's snapshot spectral imaging architecture and adjacency to medical/clinical spectral imaging extensions.
• Optomed: Handheld, AI-assisted medical imaging devices (retinal/ocular screening) relevant as a comparable go-to-market model for QCell's SAVE handheld screening device targeting non-specialist users in primary-care settings.

Direct peers

• DYSIS Medical: Specialist in computer-assisted digital colposcopy with cervical mapping (DYSISmap) for cervical intraepithelial neoplasia detection — the closest direct competitor to QCell's DSI Colposcope in the cervical screening niche.
• Karl Storz: Global leader in rigid endoscopy (otolaryngology, orthopedics, neurosurgery, urology, gynecology, laparoscopy) — the exact same surgical specialties QCell's In-Spect Endoscopes adapter targets — making it the closest direct peer for QCell's endoscopy business.
• Headwall Photonics: Hyperspectral imaging camera specialist (industrial/scientific origins) comparable to QCell's core Spectral Vision technology platform — useful as a technical/IP comparable even if Headwall is not a medical device vendor.
• 3Gen / Dermlite: Market-leading dermatoscope maker for skin lesion diagnosis by dermatologists — directly comparable to QCell's Spectral View Dermoscope in the dermatology imaging segment.

Broad incumbents

• Olympus Medical: Broad incumbent in flexible/rigid endoscopy with NBI (narrow band imaging) — an alternative spectral-adjacent technique that competes directly against QCell's spectral endoscopy value proposition across multiple surgical specialties.
• Hologic: Incumbent in women's health and cervical cancer screening (ThinPrep, NovaSure, Panther molecular diagnostics) — a strategic comparable for QCell's DSI Colposcope and SAVE cervical cancer/FGS screening franchise.
• Stryker: Major surgical/endoscopy imaging and visualization incumbent; pursues spectral/AI-augmented imaging roadmaps across orthopedic, neuro, and general surgery — directly relevant competitive gravity on QCell's In-Spect roadmap.
• Revvity (formerly PerkinElmer Life Sciences & Diagnostics): Analytical and spectral imaging instrumentation leader; relevance to QCell lies in the broader spectral imaging analytical instruments category and adjacent potential channel/technology overlap in life sciences imaging.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QCell P.C.